- call +1-201-465-4211
- email sales@mrinsights.biz
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.
Scope of the Report:
This report studies the Graft Versus Host Disease (GVHD) Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Graft Versus Host Disease (GVHD) Treatment market by product type and applications/end industries.
The growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market.
The Americas is expected to be the major revenue contributor to the GVHD treatment market by 2021. The increasing number of transplantation procedures and the growing healthcare infrastructure, will fuel the growth prospects of the market in this region. Moreover, the increasing cases of organ failures due to the unhealthy lifestyle and dietary habits of the people and the approvals of new drugs for the treatment of GVHD, will also drive the market’s growth in this region.
The global Graft Versus Host Disease (GVHD) Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Graft Versus Host Disease (GVHD) Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Bristol-Myers Squibb
Abbott
AbbVie
Allergan
Anterogen
Astellas Pharma
Athersys
Caladrius
Eli Lilly
GlaxoSmithKline
Glenmark
Kadmon Holdings
Osiris Therapeutics
Sanofi
Shire
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Monoclonal Antibodies
MTOR Inhibitors
Tyrosine Kinase Inhibitors
Thalidomide
Etanercept
Market Segment by Applications, can be divided into
Acute Graft Versus Host Disease (aGvHD)
Chronic Graft Versus Host Disease (cGvHD)
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Graft Versus Host Disease (GVHD) Treatment Market Overview
1.1 Product Overview and Scope of Graft Versus Host Disease (GVHD) Treatment
1.2 Classification of Graft Versus Host Disease (GVHD) Treatment by Types
1.2.1 Global Graft Versus Host Disease (GVHD) Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Types in 2017
1.2.3 Monoclonal Antibodies
1.2.4 MTOR Inhibitors
1.2.5 Tyrosine Kinase Inhibitors
1.2.6 Thalidomide
1.2.7 Etanercept
1.3 Global Graft Versus Host Disease (GVHD) Treatment Market by Application
1.3.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Acute Graft Versus Host Disease (aGvHD)
1.3.3 Chronic Graft Versus Host Disease (cGvHD)
1.4 Global Graft Versus Host Disease (GVHD) Treatment Market by Regions
1.4.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Graft Versus Host Disease (GVHD) Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Graft Versus Host Disease (GVHD) Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Graft Versus Host Disease (GVHD) Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Graft Versus Host Disease (GVHD) Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Graft Versus Host Disease (GVHD) Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Graft Versus Host Disease (GVHD) Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Bristol-Myers Squibb
2.1.1 Business Overview
2.1.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 Abbott
2.2.1 Business Overview
2.2.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Abbott Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 AbbVie
2.3.1 Business Overview
2.3.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 AbbVie Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Allergan
2.4.1 Business Overview
2.4.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Allergan Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.5 Anterogen
2.5.1 Business Overview
2.5.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Anterogen Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.6 Astellas Pharma
2.6.1 Business Overview
2.6.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.7 Athersys
2.7.1 Business Overview
2.7.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Athersys Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.8 Caladrius
2.8.1 Business Overview
2.8.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Caladrius Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.9 Eli Lilly
2.9.1 Business Overview
2.9.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.10 GlaxoSmithKline
2.10.1 Business Overview
2.10.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.11 Glenmark
2.11.1 Business Overview
2.11.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Glenmark Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.12 Kadmon Holdings
2.12.1 Business Overview
2.12.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.13 Osiris Therapeutics
2.13.1 Business Overview
2.13.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.14 Sanofi
2.14.1 Business Overview
2.14.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Sanofi Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.15 Shire
2.15.1 Business Overview
2.15.2 Graft Versus Host Disease (GVHD) Treatment Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Shire Graft Versus Host Disease (GVHD) Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Graft Versus Host Disease (GVHD) Treatment Market Competition, by Players
3.1 Global Graft Versus Host Disease (GVHD) Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Graft Versus Host Disease (GVHD) Treatment Players Market Share
3.2.2 Top 10 Graft Versus Host Disease (GVHD) Treatment Players Market Share
3.3 Market Competition Trend
4 Global Graft Versus Host Disease (GVHD) Treatment Market Size by Regions
4.1 Global Graft Versus Host Disease (GVHD) Treatment Revenue and Market Share by Regions
4.2 North America Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
5 North America Graft Versus Host Disease (GVHD) Treatment Revenue by Countries
5.1 North America Graft Versus Host Disease (GVHD) Treatment Revenue by Countries (2013-2018)
5.2 USA Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
6 Europe Graft Versus Host Disease (GVHD) Treatment Revenue by Countries
6.1 Europe Graft Versus Host Disease (GVHD) Treatment Revenue by Countries (2013-2018)
6.2 Germany Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
6.4 France Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Revenue by Countries
7.1 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Revenue by Countries (2013-2018)
7.2 China Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
7.5 India Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
8 South America Graft Versus Host Disease (GVHD) Treatment Revenue by Countries
8.1 South America Graft Versus Host Disease (GVHD) Treatment Revenue by Countries (2013-2018)
8.2 Brazil Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Graft Versus Host Disease (GVHD) Treatment by Countries
9.1 Middle East and Africa Graft Versus Host Disease (GVHD) Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Graft Versus Host Disease (GVHD) Treatment Revenue and Growth Rate (2013-2018)
10 Global Graft Versus Host Disease (GVHD) Treatment Market Segment by Type
10.1 Global Graft Versus Host Disease (GVHD) Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Graft Versus Host Disease (GVHD) Treatment Market Forecast by Type (2018-2023)
10.3 Monoclonal Antibodies Revenue Growth Rate (2013-2023)
10.4 MTOR Inhibitors Revenue Growth Rate (2013-2023)
10.5 Tyrosine Kinase Inhibitors Revenue Growth Rate (2013-2023)
10.6 Thalidomide Revenue Growth Rate (2013-2023)
10.7 Etanercept Revenue Growth Rate (2013-2023)
11 Global Graft Versus Host Disease (GVHD) Treatment Market Segment by Application
11.1 Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Application (2013-2018)
11.2 Graft Versus Host Disease (GVHD) Treatment Market Forecast by Application (2018-2023)
11.3 Acute Graft Versus Host Disease (aGvHD) Revenue Growth (2013-2018)
11.4 Chronic Graft Versus Host Disease (cGvHD) Revenue Growth (2013-2018)
12 Global Graft Versus Host Disease (GVHD) Treatment Market Size Forecast (2018-2023)
12.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size Forecast (2018-2023)
12.2 Global Graft Versus Host Disease (GVHD) Treatment Market Forecast by Regions (2018-2023)
12.3 North America Graft Versus Host Disease (GVHD) Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Graft Versus Host Disease (GVHD) Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Revenue Market Forecast (2018-2023)
12.6 South America Graft Versus Host Disease (GVHD) Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Graft Versus Host Disease (GVHD) Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Graft Versus Host Disease (GVHD) Treatment Picture
Table Product Specifications of Graft Versus Host Disease (GVHD) Treatment
Table Global Graft Versus Host Disease
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
